The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.
Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.
The conversation humorously suggests that elites with full hair are suppressing a hair loss cure to maintain their dating advantage. It mentions treatments like hair systems, hair transplants, and medications such as Minoxidil and finasteride.
The conversation is about a user's one-year progress after a 3,200 graft FUE hair transplant and their use of oral finasteride and minoxidil. People are impressed with the results and are discussing the effectiveness and cost of the treatment.
The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.
A user shared their excitement about starting finasteride for hair loss after trying various ineffective methods. Other users discussed their experiences with finasteride, including shedding phases and side effects, with one mentioning using topical finasteride and minoxidil.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
The conversation is about the accidental taste of Nizoral shampoo, which contains ketoconazole, during hair washing. Specific hair loss treatments mentioned are Minoxidil, Finasteride, and RU58841.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
The user experienced significant hair loss on the scalp, eyebrows, eyelashes, and pubic area, along with itchy, flaky skin and red patches. They have a history of eczema and dermatitis and suspect that stopping shampoo use and taking Ritalin may have contributed to the issue.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.
The user is experiencing severe hair loss despite using treatments like DUT, oral minoxidil, ketoconazole, RU58841, and vitamins. They plan to buzz their hair due to the ongoing hair fall and its impact on their mental health and self-esteem.
The conversation discusses converting liquid minoxidil into a foam version to save money. The user is exploring if a foam sprayer can achieve this or if additional ingredients are needed.
User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.
The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.
The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.
Using ketoconazole shampoo for seborrheic dermatitis is generally fine, but opinions vary on frequency, with some suggesting every other day and others less often. Proper scalp cleaning is emphasized to prevent itching and burning.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
Taking Minoxidil topically for hair loss and the results, which included jokes about castration, Daenerys Targaryenism, and a hair system. People in the conversation also shared positive affirmations and humorous comments.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation is about hair regrowth treatments, including ketoconazole, vitamins, fish oil, collagen, pumpkin seed oil, rosemary, and dermal rolling. Users suggest trying finasteride and intense weight training to enhance results.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.